[Federal Register: March 5, 2003 (Volume 68, Number 43)]
[Notices]
[Page 10483]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05mr03-67]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Dietary Supplement Subcommittee of the Food Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Dietary Supplement Subcommittee of the Food
Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on March 25, 2003, from 8
a.m. to 5 p.m.
Location: Holiday Inn (Ballrooms A and B), 10000 Baltimore Ave.,
College Park, MD, 301-345-6700.
Contact Person: Constance J. Hardy, Center for Food Safety and
Applied Nutrition (HFS-811), Food and Drug Administration, 5100 Paint
Branch Pkwy., College Park, MD 20740, 301-436-1433, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 10564. Please call the Information Line for
up-to-date information on this meeting.
Agenda: To be a dietary supplement as defined in section 201(ff) of
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321(ff)),
a product must contain at least one ``dietary ingredient.'' Section
201(ff)(1) of the act lists those substances that are considered
``dietary ingredients.'' Among other things, the term ``dietary
ingredient'' includes a metabolite of any other dietary ingredient
defined in section 201(ff)(1) of the act. The statute is ambiguous,
however, as to what substances are, or are not, metabolites of other
substances. The practical result of this ambiguity is that it is often
difficult to determine whether a particular substance meets the dietary
ingredient definition and, therefore, whether products containing the
substance can be marketed as dietary supplements. The purpose of this
meeting is to explore whether there are recognized scientific
principles that would facilitate reaching a conclusion as to whether a
particular substance is a ``metabolite'' of another substance that is a
``dietary ingredient'' defined in the act and, therefore, is itself a
dietary ingredient within the scope of section 201(ff)(1) of the act.
The background material for this meeting will be posted on the Internet
when available or 1-working day before the meeting at http://
www.cfsan.fda.gov/
[tilde]lrd/vidtel.html.
www.cfsan.fda.gov/[tilde]lrd/vidtel.html.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by March 17,
2003. Oral presentations from the public will be scheduled on March 25,
2003, between approximately 11 a.m. and 3 p.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before March 20, 2003,
and submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Constance J. Hardy
at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: February 27, 2003.
Linda Arey Skladany,
Associate Commissioner for External Relations.
[FR Doc. 03-5073 Filed 3-4-03; 8:45 am]
BILLING CODE 4160-01-S